Jennifer Callahan
Finanzdirektor/CFO bei CINGULATE INC.
Vermögen: 1 960 $ am 30.04.2024
Profil
Jennifer L.
Callahan is currently working as a Controller at Cingulate Works, Inc. She also holds the position of Secretary, SVP, CFO & CAO at Cingulate, Inc. since 2017.
Ms. Callahan completed her undergraduate degree at Creighton University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
CINGULATE, INC.
0,06% | 15.03.2024 | 2 333 ( 0,06% ) | 1 960 $ | 30.04.2024 |
Aktive Positionen von Jennifer Callahan
| Unternehmen | Position | Beginn |
|---|---|---|
| CINGULATE INC. | Finanzdirektor/CFO | 29.01.2024 |
Cingulate Works, Inc.
 Cingulate Works, Inc. Pharmaceuticals: MajorHealth Technology Cingulate Works, Inc. is a clinical stage biopharmaceutical company which operates drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products. Its products designed to improve the lives of patients suffering from burdensome daily dosing regimens and suboptimal treatment outcomes. The company was founded by Shane J. Schaffer, Matthew N. Brams, Raul R. Silva & Craig Steven Gilgallon in 2013 and is headquartered in Kansas City, KS. | Comptroller/Controller/Auditor | - |
Ausbildung von Jennifer Callahan
| Creighton University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| CINGULATE INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Cingulate Works, Inc.
Cingulate Works, Inc. Pharmaceuticals: MajorHealth Technology Cingulate Works, Inc. is a clinical stage biopharmaceutical company which operates drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products. Its products designed to improve the lives of patients suffering from burdensome daily dosing regimens and suboptimal treatment outcomes. The company was founded by Shane J. Schaffer, Matthew N. Brams, Raul R. Silva & Craig Steven Gilgallon in 2013 and is headquartered in Kansas City, KS. | Health Technology |
